Business Wire

Azul Addresses the Java Runtime Security Blind Spot Autonomous AI Can Now Exploit

17.6.2026 15:00:00 CEST | Business Wire | Press Release

Share

Azul, the trusted leader in enterprise Java for today’s AI and cloud-first world, today launched a free JVM vulnerability risk assessment to address the blind spot that autonomous AI exploitation tools are increasingly able to find. With mean time to exploit (MTTE) collapsing from months to days or hours, the unmanaged Java estate has become an urgent enterprise security vulnerability. Azul’s assessment gives DevOps and SecOps teams complete visibility into the hidden risks embedded in the runtime of their Java estate before threat actors get there first, and is designed to complement the broader security, licensing and compliance solutions and services delivered by Azul’s trusted partners.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617352753/en/

Azul's JVM Vulnerability Risk Assessment dashboard.

The Threat Landscape Has Transformed

For most of Java’s enterprise history, a sophisticated exploit required a sophisticated attacker. Zero-day discovery and weaponization were largely the domain of nation-states and elite offensive security teams. The barrier was expertise — deep JVM knowledge, reverse engineering and months of painstaking technical effort.

That barrier has collapsed. Anthropic’s Claude Mythos demonstrates that AI can autonomously uncover previously unknown vulnerabilities and generate working exploit paths at scale — without human expertise. What once required deep, specialized expertise can now be accomplished with little more than an advanced AI model and an API key.

The result is an expanding population of potential attackers. MTTE — once measured in months — can now collapse to days or hours. Meanwhile, most enterprises still patch non-critical Common Vulnerabilities and Exposures (CVEs) on a “best effort” basis, leaving extended windows of exposure between vulnerability disclosure and remediation. For large, complex Java estates with legacy versions in production, embedded or unmanaged JVMs and incomplete runtime visibility, that gap is a critical security and compliance liability.

The JVM Vulnerability Risk Assessment — See Everything, Prioritize What Matters

Azul’s JVM vulnerability risk assessment is available at no cost, direct from Azul and via select Azul partners. In a single engagement, organizations receive:

  • Executive-ready security dashboard: A visual summary of the entire Java estate, broken down by risk tier, publisher and Java version — designed for CxO-level consumption and board reporting.
  • Risk-by-version breakdown: Identification of the specific Java versions driving the highest exposure, so remediation effort can be directed where it matters most rather than spread uniformly.
  • Key Risk Indicators (KRIs) for AI-driven exploits: Visibility into which JVMs carry active Known Exploited Vulnerability (KEV) exposure — the highest-priority threat class recognized in the U.S. government’s CISA KEV catalog — as well as which instances are end-of-life or running below the current patch baseline.
  • Prioritized remediation roadmap: Concrete next steps ranked by impact, including which workloads to patch first, which to migrate off unsupported runtimes, and how to address extended support needs for legacy environments that cannot be immediately modernized.

“Through our strategic partnership with Azul, we significantly reduced our security risk level with our Java applications and Java-based infrastructure, which certainly helps me sleep better at night,” said Jenny Nelson, head of ICT & Digital at Newcastle City Council. “In addition, the benefits of switching to Azul Core as our JVM are clear. Our Java estate is now consistent, standardized, easier to maintain, and has brought a level of simplicity that’s a huge benefit to our organization.”

The assessment is purpose-built for the risk environment AI-driven attackers have created: one in which the gap between assumed security posture and actual security posture is measured not in audit findings, but in active exploits.

Why Security Patch Velocity is the Frontline Defense

Java’s quarterly updates are the primary mechanism by which known vulnerabilities are remediated. But in an environment where autonomous AI systems continuously discover new vulnerabilities or chain together previously known CVEs into exploits, the pace of standard patch deployment is no longer sufficient on its own. Azul’s enterprise Java platform addresses this challenge through a multi-layered approach designed for large, complex Java estates:

  • Stable Critical Patch Updates (CPUs): Quarterly, production-safe patches containing only current CVE fixes. Azul Core is the only OpenJDK distribution which provides security-only updates, intended for immediate deployment without disrupting live environments.
  • Out-of-cycle emergency fixes: As vulnerabilities are discovered which demand immediate remediation, Azul provides security-only emergency fixes, collaborating with the Java community to help ensure safe delivery.
  • Full-stack visibility: Azul surfaces every JVM instance across the enterprise estate, including embedded and unmanaged runtimes that standard asset discovery typically misses — closing the gaps before they can be exploited.

The zero-day problem remains the hardest frontier. No scanner, SIEM (Security Information and Event Management), or EDR (Endpoint Detection and Response) platform can detect a vulnerability that has not yet been disclosed. Against unknown exposure, organizations maintaining a fully current Java estate are materially harder to exploit as they continuously remove outdated runtimes and previously exposed attack surfaces from production, minimizing the footprint that agentic AI exploits can target.

Elevated Stakes for Regulated Enterprises

Organizations in financial services, healthcare, utilities and government face a compounding challenge. They operate some of the largest and most complex Java estates in existence, and they face the strictest regulatory obligations. Frameworks including PCI-DSS, SOX, HIPAA, DORA, NERC CIP and FedRAMP all require demonstrable visibility into deployed software versions, timely vulnerability remediation and documented patch history.

Autonomous AI exploitation tools do not distinguish between regulated and unregulated targets. But the consequences of a breach in a regulated environment — and the burden of demonstrating adequate security posture to auditors — make estate visibility and rapid CPU deployment not merely a best practice but a compliance requirement.

“Anthropic’s Mythos has shown that AI can now discover and weaponize vulnerabilities on its own — including flaws that survived decades of human review. That’s the real lesson for every CISO: the deep expertise that used to stand between attackers and your software estate is no longer a barrier,” said Scott Sellers, co-founder and CEO of Azul. “The unpatched JVM is already a growing liability, not a future one. Azul’s JVM vulnerability risk assessment was created to help security leaders find and close that exposure before AI-driven attackers can exploit it.”

Azul’s JVM vulnerability risk assessment maps JVM exposure, KEV risk and patch gaps across the entire enterprise Java estate and delivers a concrete remediation roadmap to close them. The assessment can be utilized as a standalone vulnerability analysis specific to a Java runtime estate or can be augmented into existing security, licensing and compliance solutions and services offered by Azul partners.

To understand your organization’s exposure, request a free JVM vulnerability risk assessment today.

FAQs

How do I find unmanaged or embedded JVMs across my enterprise Java estate?
Azul’s JVM vulnerability risk assessment surfaces every JVM instance across your environment — including embedded and unmanaged runtimes that standard asset discovery misses — and delivers a prioritized remediation roadmap to close the gaps.

How do I know which Java versions in my environment are the highest security risk?
Azul’s JVM vulnerability risk assessment breaks down your estate by risk tier, Java version and publisher, and identifies which JVMs carry active Known Exploited Vulnerability (KEV) exposure from the CISA KEV catalog.

What’s the best way to reduce the attack surface autonomous AI tools can exploit in my Java environment?
Azul continuously removes outdated runtimes and closes patch gaps across the entire Java estate — including legacy and unmanaged JVMs — minimizing the footprint autonomous AI exploitation tools can target.

Why are Critical Patch Updates (CPUs) important?
A CPU contains only security fixes, applied on top of the previous, field-stabilized release. That sets these updates apart from the Patch Set Updates (PSUs) that all other OpenJDK builds provide. PSUs bundle security updates, new features and bug fixes — typically measured in the hundreds — that demand far more testing before they can be safely deployed in production. Azul Core is the only OpenJDK distribution which provides CPUs, allowing teams to deploy urgent security fixes rapidly, with much lower risk of regression.

Why are unpatched Java environments a growing security liability?
Autonomous AI tools have collapsed mean time to exploit from months to days or hours, making unpatched JVMs and unmanaged runtimes an urgent liability — underscored by how quickly Mythos-class capability escaped its intended containment. Maintaining a current Java estate with full visibility is now the primary defense.

About Azul

Azul is the trusted leader in enterprise Java for today’s AI and cloud-first world. Its open source-based Java platform empowers organizations to optimize the entire Java lifecycle to accelerate performance, strengthen security, reduce licensing and cloud costs, and boost developer productivity. Azul powers mission-critical systems for 36% of the Fortune 100, 50% of the Forbes Top 10 World’s Most Valuable Brands, and the world’s top 10 financial trading companies. Learn more at azul.com and follow @azulsystems.​

View source version on businesswire.com: https://www.businesswire.com/news/home/20260617352753/en/

Contacts

Media Contact for Azul:
Treble -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Ftreblepr.com&es
heet=54554107&newsitemid=20260617352753&lan=en-US&anchor=Treble&index=5&md5=2834
90e2a2bc31dfc508c83d4c47b63f
Josh Georgiou
azul@treblepr.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press Release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press Release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 14:00:00 CEST | Press Release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press Release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye